Mortality following bone metastasis and skeletal-related events among patients 65 years and above with lung cancer: A population-based analysis of U.S. Medicare beneficiaries, 1999-2006

Lung India

Volumn 30, Issue 1, 2013, Pages 20-26

  Sathiakumar, Nalini ^a   Delzell, Elizabeth ^a   Morrisey, Michael A ^a   Falkson, Carla ^b   Yong, Mellissa ^c   Chia, Victoria ^c   Blackburn, Justin ^a   Arora, Tarun ^a   Kilgore, Meredith L ^a  

^a UNIVERSITY OF ALABAMA AT BIRMINGHAM   (United States)

^b UNIVERSITY OF ALABAMA SCHOOL OF MEDICINE   (United States)

^c AMGEN INC   (United States)

Author keywords

Claims; distant stage; fractures; mortality; SEER

Indexed keywords

AGED; BONE DISEASE; BONE METASTASIS; CANCER REGISTRY; FEMALE; FOLLOW UP; HUMAN; LUNG CANCER; MAJOR CLINICAL STUDY; MALE; MEDICARE; MORTALITY; REVIEW;

EID: 84876891294     PISSN: 09702113     EISSN: 0974598X     Source Type: Journal    
DOI: 10.4103/0970-2113.106127     Document Type: Review

References (39)

1. Kohler BA, Ward E, McCarthy BJ, Schymura MJ, Ries LA, Eheman C, et al. Annual report to the nation on the status of cancer, 1975-2007, featuring tumors of the brain and other nervous system. J Natl Cancer Inst 2011;103:714-36.
2. American Cancer Society Facts and Figures 2012. American Cancer Society, Atlanta, Georgia [Internet]. Available from: http://www.cancer.org/acs/groups/ content/@epidemiologysurveilance/documents/document/acspc-031941.pdf [Last cited on 2012 Apr 3].
3. Jemal A, Siegel R, Xu J, Ward E. Cancer statistics, 2010. CA Cancer J Clin 2010;60:277-300.
4. Coleman RE. Risks and benefits of bisphosphonates. Br J Cancer 2008;98:1736-40.
5. Roodman GD. Biology of osteoclast activation in cancer. J Clin Oncol 2001;19:3562-71.
6. Coleman RE. Skeletal complications of malignancy. Cancer 1997;80(8 Suppl):1588-94.
7. Coleman RE. Management of bone metastases. Oncologist 2000;5:463-70.
8. Coleman RE. Bisphosphonates: Clinical experience. Oncologist 2004;9(Suppl 4):14-27.
9. Berenson JR, Rajdev L, Broder M. Managing bone complications of solid tumors. Cancer Biol Ther 2006;5:1086-9.
10. Delea T, Langer C, McKiernan J, Liss M, Edelsberg J, Brandman J, et al. The cost of treatment of skeletal-related events in patients with bone metastases from lung cancer. Oncology 2004;67:390-6.
11. Rosen LS, Gordon D, Tchekmedyian NS, Yanagihara R, Hirsh V, Krzakowski M, et al. Long-term efficacy and safety of zoledronic acid in the treatment of skeletal metastases in patients with nonsmall cell lung carcinoma and other solid tumors: A randomized, Phase III, double-blind, placebo-controlled trial. Cancer 2004;100:2613-21.
12. Potosky AL, Riley GF, Lubitz JD, Mentnech RM, Kessler LG. Potential for cancer related health services research using a linked Medicare-tumor registry database. Med Care 1993;31:732-48.
13. Warren JL, Klabunde CN, Schrag D, Bach PB, Riley GF. Overview of the SEER-Medicare data: Content, research applications, and generalizability to the United States elderly population. Med Care 2002;40(8 Suppl):IV-3-18.
14. Gornick ME, Warren JL, Eggers PW, Lubitz JD, De Lew N, Davis MH, et al. Thirty years of medicare: Impact on the covered population. Health Care Financ Rev 1996r;18:179-237.
15. Romano PS, Roos LL, Jollis JG. Adapting a clinical comorbidity index for use with ICD-9-CM administrative data: Differing perspectives. J Clin Epidemiol 1993;46:1075-9.
16. Quan H, Sundararajan V, Halfon P, Fong A, Burnand B, Luthi JC, et al. Coding algorithms for defining comorbidities in ICD-9-CM and ICD-10 administrative data. Med Care 2005;43:1130-9.
17. Gooley TA, Leisenring W, Crowley J, Storer BE. Estimation of failure probabilities in the presence of competing risks: New representations of old estimators. Stat Med 1999;18:695-706.
18. Kalbfleisch JD, Prentice RL. The statistical analysis of failure time data. New York, John Wiley & Sons, Inc; 1980.
19. Cox DR. Regression models and life-tables (with discussion). J Royal Statistical Society 1972;34:187-220.
20. SSAS.com [Internet]. SAS Institute Inc. 100 SAS Campus Drive, Cary, NC, 27513-2414, USA [updated 2012 May 25; cited 2012 Dec 6]. Available from URL: http://www.sas.com.
21. Kosteva J, Langer C. The changing landscape of the medical management of skeletal metastases in nonsmall cell lung cancer. Curr Opin Oncol 2008;20:155-61.
22. Hirsh V. Skeletal disease contributes substantially to morbidity and mortality in patients with lung cancer. Clin Lung Cancer 2009;10:223-9.
23. Iordanidou L, Trivizaki E, Saranti S, Georgakopoulos A, Bolanos N, Baltagiannis N, et al. Is there a role of whole body bone scan in early stages of non small cell lung cancer patients. J BUON 2006;11:491-7.
24. Schirrmeister H, Arslandemir C, Glatting G, Mayer-Steinacker R, Bommer M, Dreinhöfer K, et al. Omission of bone scanning according to staging guidelines leads to futile therapy in non-small cell lung cancer. Eur J Nucl Med Mol Imaging 2004;31:964-8.
25. Michel F, Solèr M, Imhof E, Perruchoud AP. Initial staging of non-small cell lung cancer: Value of routine radioisotope bone scanning. Thorax 1991;46:469-73.
26. Tornyos K, Garcia O, Karr B, LeBeaud R. A correlation study of bone scanning with clinical and laboratory findings in the staging of nonsmall-cell lung cancer. Clin Nucl Med 1991;16:107-9.
27. Salvatierra A, Baamonde C, Llamas JM, Cruz F, Lopez-Pujol J. Extrathoracic staging of bronchogenic carcinoma. Chest 1990;97:1052-8.
28. Osada H, Nakajima Y, Taira Y, Yokote K, Noguchi T. The role of mediastinal and multi-organ CT scans in staging presumable surgical candidates with non-small-cell lung cancer. Jpn J Surg 1987;17:362-8.
29. Turner P, Haggith JW. Preoperative radionuclide scanning in bronchogenic carcinoma. Br J Dis Chest 1981;75:291-4.
30. Hooper RG, Beechler CR, Johnson MC. Radioisotope scanning in the initial staging of bronchogenic carcinoma. Am Rev Respir Dis 1978;118:279-86.
31. Ramsdell JW, Peters RM, Taylor AT Jr, Alazraki NP, Tisi GM. Multiorgan scans for staging lung cancer. Correlation with clinical evaluation. J Thorac Cardiovasc Surg 1977;73:653-9.
32. Kosteva JL. Incidence and distribution of skeletal metastases in NSCLC in the era of PET. Lung Cancer 2004;46:S45.
33. Tsuya A, Kurata T, Tamura K, Fukuoka M. Skeletal metastases in non-small cell lung cancer: A retrospective study. Lung Cancer 2007;57:229-32.
34. Coleman RE. Metastatic bone disease: Clinical features, pathophysiology and treatment strategies. Cancer Treat Rev 2001;27:165-76.
35. Coleman RE. Clinical features of metastatic bone disease and risk of skeletal morbidity. Clin Cancer Res 2006;12:6243s-9s.
36. Sun JM, Ahn JS, Lee S, Kim JA, Lee J, Park YH, et al. Predictors of skeletal-related events in non-small cell lung cancer patients with bone metastases. Lung Cancer 2011;71:89-93.
37. Sathiakumar N, Delzell E, Morrisey MA, Falkson C, Yong M, Chia V, et al. Mortality following bone metastasis and skeletal-related events among men with prostate cancer: A population-based analysis of US Medicare beneficiaries, 1999-2006. Prostate Cancer Prostatic Dis 2011;14:177-83.
38. Sathiakumar N, Delzell E, Morrisey MA, Falkson C, Yong M, Chia V, et al. Mortality following bone metastasis and skeletal-related events among women with breast cancer: A population-based analysis of U.S. Medicare beneficiaries, 1999-2006. Breast Cancer Res Treat 2012;131:231-8.
39. SEER-Medicare: Data Limitations. National Cancer Institute [Internet] Available from: http://healthservices.cancer.gov/seermedicare/considerations/ limitations.html. [Last cited on 2012 Apr 3]